These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 23774005

  • 21. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
    Alvarez-Lerma F, Soriano MC, Rodríguez M, Catalán M, Llorente AM, Vidart N, Garitacelaya M, Maraví E, Fernández E, Alvarado F, López M, Alvarez-Sánchez B, Espinosa J, Quintana E, Study Group of Liposomal Amphotericin B in the ICU.
    Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
    [Abstract] [Full Text] [Related]

  • 22. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.
    Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fan-Havard P, Eng RH, Patterson TF, Pottage JC, Simberkoff MS, Wolf J, Meyer RD, Gupta R, Lee LW, Gordon DS.
    Clin Infect Dis; 1996 Feb; 22(2):315-21. PubMed ID: 8838189
    [Abstract] [Full Text] [Related]

  • 23. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
    Dutta A, Palazzi DL.
    Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study.
    Slain D, Miller K, Khakoo R, Fisher M, Wierman T, Jozefczyk K.
    Clin Ther; 2002 Oct; 24(10):1636-42. PubMed ID: 12462292
    [Abstract] [Full Text] [Related]

  • 26. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
    Ramaswamy M, Peteherych KD, Kennedy AL, Wasan KM.
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
    [Abstract] [Full Text] [Related]

  • 27. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
    Rothenbühler C, Held U, Manz MG, Schanz U, Gerber B.
    Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
    [Abstract] [Full Text] [Related]

  • 28. Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundação ABC.
    Uehara RP, Sá VH, Koshimura ET, Prudente FV, Tucunduva LT, Gonçalves MS, Samano ES, del Giglio A.
    Sao Paulo Med J; 2005 Sep 01; 123(5):219-22. PubMed ID: 16358096
    [Abstract] [Full Text] [Related]

  • 29. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
    Kato H, Hagihara M, Yamagishi Y, Shibata Y, Kato Y, Furui T, Watanabe H, Asai N, Koizumi Y, Mikamo H.
    J Infect Chemother; 2018 Sep 01; 24(9):725-728. PubMed ID: 29773439
    [Abstract] [Full Text] [Related]

  • 30. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
    Hamill RJ, Sobel JD, El-Sadr W, Johnson PC, Graybill JR, Javaly K, Barker DE.
    Clin Infect Dis; 2010 Jul 15; 51(2):225-32. PubMed ID: 20536366
    [Abstract] [Full Text] [Related]

  • 31. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA, Adler-Moore JP, Schwartz J, Jensen GM, Proffitt RT.
    Antimicrob Agents Chemother; 2006 Jun 15; 50(6):2122-31. PubMed ID: 16723574
    [Abstract] [Full Text] [Related]

  • 32. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.
    Cannon JP, Fiscella R, Pattharachayakul S, Garey KW, De Alba F, Piscitelli S, Edward DP, Danziger LH.
    Invest Ophthalmol Vis Sci; 2003 May 15; 44(5):2112-7. PubMed ID: 12714650
    [Abstract] [Full Text] [Related]

  • 33. Comparison of adverse events and hospital length of stay associated with various amphotericin B formulations: sequential conventional amphotericin b/lipid versus lipid-only therapy for the treatment of invasive fungal infections in hospitalized patients.
    Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn D.
    P T; 2013 May 15; 38(5):278-87. PubMed ID: 23946621
    [Abstract] [Full Text] [Related]

  • 34. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E.
    Cancer; 2004 Feb 01; 100(3):581-9. PubMed ID: 14745876
    [Abstract] [Full Text] [Related]

  • 35. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
    Hooshmand-Rad R, Reed MD, Chu A, Gotz V, Morris JA, Weinberg J, Dominguez EA.
    Clin Ther; 2004 Oct 01; 26(10):1652-62. PubMed ID: 15598482
    [Abstract] [Full Text] [Related]

  • 36. continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.
    Falagas ME, Karageorgopoulos DE, Tansarli GS.
    PLoS One; 2013 Oct 01; 8(10):e77075. PubMed ID: 24204739
    [Abstract] [Full Text] [Related]

  • 37. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS.
    N Engl J Med; 1999 Mar 11; 340(10):764-71. PubMed ID: 10072411
    [Abstract] [Full Text] [Related]

  • 38. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M, Letscher-Bru V, Herbrecht R.
    Transpl Infect Dis; 1999 Dec 11; 1(4):273-83. PubMed ID: 11428998
    [Abstract] [Full Text] [Related]

  • 39. Hematological toxicities associated with amphotericin B formulations.
    Falci DR, da Rosa FB, Pasqualotto AC.
    Leuk Lymphoma; 2015 Dec 11; 56(10):2889-94. PubMed ID: 25629990
    [Abstract] [Full Text] [Related]

  • 40. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
    Yamazaki H, Kondo T, Aoki K, Yamashita K, Takaori-Kondo A.
    Diagn Microbiol Infect Dis; 2018 Feb 11; 90(2):123-131. PubMed ID: 29203252
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.